Emerson A. Lim
Expertise in
17
conditions

Dr. Emerson A. Lim

Hematology Oncology | Oncology
Corewell Health Gerber Hospital Cancer Care Center - Oak St
230 West Oak Street, 
Fremont, MI 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
17
conditions
Corewell Health Gerber Hospital Cancer Care Center - Oak St
230 West Oak Street, 
Fremont, MI 

Overview

Emerson Lim is a Hematologist Oncology specialist and an Oncologist practicing medicine in Fremont, Michigan.

Dr. Lim is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Clear Cell Sarcoma, Chromophobe Renal Cell Carcinoma, and WT1-Related Wilms Tumor Syndromes.

Dr. Lim is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 25 peer reviewed articles and participating in 8 clinical trials. Dr. Lim is currently accepting new patients.

Graduate Institution

New York University School Of Medicine

Specialties

Hematology Oncology
Oncology

Licenses

Internal Medicine in NY

Board Certifications

American Board Of Internal Medicine

Fellowships

New York-Presbyterian University Hospital of Columbia and Cornell

Hospital Affiliations

Corewell Health Ludington Hospital
Corewell Health Reed City Hospital
Corewell Health Gerber Hospital
Corewell Health Pennock Hospital
Corewell Health Grand Rapids Hospitals
Corewell Health Greenville Hospital
Spectrum Health
Spectrum Health United Hospital
Corewell Health Ludington Hospital
Corewell Health Reed City Hospital
Corewell Health Gerber Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Associates
  • MEDICARE MAPD
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Corewell Health Gerber Hospital Cancer Care Center - Oak St
230 West Oak Street, Fremont, MI 49412

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 2
Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers
Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers
Enrollment Status: Active_not_recruiting
Publish Date: March 06, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1-2 Dose-escalation and Expansion Study of ST101 in Patients With Advanced Unresectable and Metastatic Solid Tumors
A Phase 1-2 Dose-escalation and Expansion Study of ST101 in Patients With Advanced Unresectable and Metastatic Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 09, 2026
Intervention Type: Drug, Radiation
Study Phase: Phase 1/Phase 2
A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: July 03, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
Enrollment Status: Terminated
Publish Date: July 15, 2022
Intervention Type: Drug, Biological
Study Drugs: IL-2, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 11, 2022
Intervention Type: Drug
Study Drug: 18F- DCFPyL PET/CT
Study Phase: Phase 2/Phase 3
Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers
Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers
Enrollment Status: Active_not_recruiting
Publish Date: May 11, 2022
Intervention Type: Procedure, Drug
Study Drug: [F-18] DCFPyL
Study Phase: Phase 2
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
View 7 Less Clinical Trials

25 Total Publications

Prostate-Specific Membrane Antigen Positron Emission Tomography-Detected Intrahepatic Cholangiocarcinoma in a Patient With Metastatic Castration-Resistant Prostate Cancer: Dual Cancer Management With Pluvicto and Intensity-Modulated Radiation Therapy.
Prostate-Specific Membrane Antigen Positron Emission Tomography-Detected Intrahepatic Cholangiocarcinoma in a Patient With Metastatic Castration-Resistant Prostate Cancer: Dual Cancer Management With Pluvicto and Intensity-Modulated Radiation Therapy.
Journal: Cureus
Published: August 15, 2025
Similar Doctors
Expertise in
29
conditions
Dr. Manish K. Thakur
Hematology Oncology | Oncology
Expertise in
29
conditions
Dr. Manish K. Thakur
Hematology Oncology | Oncology
Referral may be required
Before you request

Corewell Health Gerber Hospital Cancer Care Center - Oak St

230 West Oak Street, 
Fremont, MI 
 (0.1 miles away)
231-924-1305
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Manish Thakur is a Hematologist Oncology specialist and an Oncologist practicing medicine in Fremont, Michigan. Dr. Thakur is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Testicular Cancer, Non-Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC). Dr. Thakur is board certified in American Board Of Internal Medicine. Dr. Thakur is currently accepting new patients.

Expertise in
35
conditions
Dr. Sreenivasa R. Chandana
Oncology | Hematology Oncology | Gastroenterology
Expertise in
35
conditions
Dr. Sreenivasa R. Chandana
Oncology | Hematology Oncology | Gastroenterology
Referral may be required
Before you request

The Cancer & Hematology Centers - Muskegon

6425 Harvey Street, 
Norton Shores, MI 
 (23.4 miles away)
231-737-3469
Languages Spoken:
English, Hindi, Telugu
See accepted insurances
Accepting New Patients

Sreenivasa Chandana is an Oncologist and a Hematologist Oncology provider practicing medicine in Norton Shores, Michigan. Dr. Chandana is highly rated in 35 conditions, according to our data. His clinical expertise encompasses Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Familial Colorectal Cancer, Endoscopy, and Pancreatectomy. Dr. Chandana is board certified in American Board Of Internal Medicine. Dr. Chandana is currently accepting new patients.

Expertise in
34
conditions
Dr. Kathryn B. Alguire
Oncology | Hematology Oncology
Expertise in
34
conditions
Dr. Kathryn B. Alguire
Oncology | Hematology Oncology
Referral may be required
Before you request

The Cancer & Hematology Centers - Muskegon

6425 Harvey Street, 
Norton Shores, MI 
 (23.4 miles away)
231-737-3469
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kathryn Alguire is an Oncologist and a Hematologist Oncology provider practicing medicine in Norton Shores, Michigan. Dr. Alguire is highly rated in 34 conditions, according to our data. Her clinical expertise encompasses Paget Disease of the Breast, Breast Cancer, Angiosarcoma, and Inflammatory Breast Cancer. Dr. Alguire is board certified in American Board Of Internal Medicine. Dr. Alguire is currently accepting new patients.

Frequently Asked Questions about Dr. Emerson A. Lim

How do I make an appointment with Dr. Emerson A. Lim?

You can book an appointment with Dr. Emerson A. Lim by calling their office at 231-924-1305. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Emerson A. Lim a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Emerson A. Lim is classified as an Distinguished expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Emerson A. Lim specialize in?

While Dr. Emerson A. Lim is a Hematology Oncology, they have specific expertise in Prostate Cancer, Clear Cell Sarcoma, and Chromophobe Renal Cell Carcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Emerson A. Lim participate in research or clinical trials?

Yes. Dr. Emerson A. Lim has published 25 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. Emerson A. Lim's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Emerson A. Lim accept my insurance?

Dr. Emerson A. Lim accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 231-924-1305 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lim's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 56 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile